Market Landscape: Anti-rejetion drugs

Brief:

Market landscape exploration into the likely adoption of a new anti-rejection drug for the treatment of organ transplant patients

Countries:

US

Methodology:

Qualitative and quantitative: transplant surgeons, transplant nurses; nephrologists

The research explored:

  • The prescribing legacy and potential for different routes of administration and regimens

  • The motivations for prescribing choices

  • Identified the white space needed for the new product

Delivered:

Detailed mapping of the competitive landscape highlighting the potential drivers and barriers to adoption of different current treatments allowing for the next stage of the messaging development the product position and draft messaging to ensure a successful communication strategy ready for launch

Previous
Previous

Positioning: Thoraco-abdominal endovascular device

Next
Next

Patient Experiences: Haemophilia and Inhibitors